STAT

NOVEMBER 8, 2023

As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. ” Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division.

Drug Development 336

Drug Development 336

pharmaphorum

MARCH 21, 2025

4th ALS Drug Development Summit Sara.Scarpinati Fri, 21/03/2025 - 11:24 Bookmark this

Drug Development 59

Drug Development 59

LifeProNow

FEBRUARY 2, 2025

January 30, 2025: “The U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults.

Adverse Reactions 130

Adverse Reactions Labelling Drug Development 130

pharmaphorum

MARCH 31, 2025

Accelerating Breakthroughs in Immunodermatology Drug Development Sara.Scarpinati Mon, 31/03/2025 - 14:18 Bookmark this

Drug Development 52

Drug Development 52

Express Pharma

JANUARY 3, 2025

Innovation must remain at the core of our efforts Kiran Mazumdar-Shaw, Chairperson, Biocon and Biocon Biologics Indias biopharma sector, currently valued at over $54 billion, is on a promising trajectory, and projected to reach nearly $63 billion by 2025. First and foremost, innovation must remain at the core of our efforts.

Biosimilars 105

Biosimilars Vaccines Hospitals Drug Development 105

Express Pharma

DECEMBER 2, 2024

Additionally, Novo Nordisk’s novel Phase III candidate, NN-9932, which is expected to be launched by the end of 2025, has the highest probability of success among all drugs in this category, with a 35 per cent likelihood of approval (LoA).” Novo Nordisk and Eli Lilly have already reaped substantial rewards in the injectable segment.

Labelling 126

Labelling Diabetes Drug Development 126

pharmaphorum

DECEMBER 21, 2021

During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals.

Drug Development 98

Drug Development Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

pharmaphorum

NOVEMBER 1, 2024

Join the Proteomic Based Drug Discovery Summit 2025 to stay updated on the latest trends in drug development and network with industry experts. Visit our website to register and be part of this exciting event.

Drug Development 52

Drug Development 52

pharmaphorum

JANUARY 23, 2025

Stay ahead of the game with our 2025 predictions and AI trends for pharma executives. Explore how AI is transforming drug development, healthcare, and regulatory processes.

Drug Development 52

Drug Development 52

pharmaphorum

FEBRUARY 4, 2025

Explore the future of clinical trials in the pharmaceutical industry, focusing on AI advancements, GLP-1 competition, and the evolving landscape of drug development in Pharma 2025.

Drug Development 52

Drug Development 52

Putting Patients First Blog

JANUARY 22, 2025

2025 Health Leadership Conference takes on The Future of Leadership January 22, 2025 By: Leah Poffenberger, Senior Manager, Communications Leadership health care often comes with unique challenges in an ever-changing ecosystem. To learn more about the 2025 Health Leadership Conference, visit the conference website.

Communication 52

Communication Diabetes Drug Development 52

BioPharma Dive

JANUARY 23, 2025

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Drug Development 67

Drug Development 67

PharmExec

FEBRUARY 17, 2025

Pharm Execs 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.

Drug Development 52

Drug Development 52

Pharma IQ

JANUARY 22, 2025

Discover how advancements in unified systems, patient diversity, and regulatory submissions will accelerate drug development & improve patient outcomes.

Drug Development 52

Drug Development 52

Pharma Marketing Network

JANUARY 29, 2025

In 2025, pharmaceutical trends are redefining how brands connect with healthcare professionals (HCPs), patients, and stakeholders. With machine learning and big data analytics, companies can now predict market trends, enhance drug development, and create hyper-personalized campaigns.

Communication 52

Communication Drug Development 52

pharmaphorum

DECEMBER 22, 2022

In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. The Parma site is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025.

Drug Development 98

Drug Development 98

FDA Law Blog: Biosimilars

JANUARY 16, 2025

Hyman, Phelps & McNamara PC, (HPM), which will mark its 45thAnniversary on March 17, 2025, is pleased to announce that it is increasing its directors, counsel, and associates as it starts the year. Richardson has been promoted to Director.

Pharmaceutical Manufacturing 59

Pharmaceutical Manufacturing Drug Development 59

European Pharmaceutical Review

AUGUST 1, 2022

The DDiCT project will be co-led by Bristol Myers Squibb (BMS)’s Disability Advancement Workplace Network (DAWN) and the Global Drug Development Team. The goal is to “ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies,” a statement said.

Drug Development 122

Drug Development Pharmaceutical Companies Pharmaceutical Companies 122

European Pharmaceutical Review

DECEMBER 15, 2023

The deal also includes around 400 staff employed by Alkermes in drug development and manufacturing. Additionally, Alkermes and Novo Nordisk plan to agree subcontracting arrangements to continue certain work currently performed at the facility, potentially until the end of 2025. The transaction is expected to close in mid-2024.

Drug Development 104

Drug Development 104

Express Pharma

MARCH 26, 2025

Japans Ministry of Health, Labor, and Welfare (MHLW) announced a new 10-year government fund in January 2025 to support innovative drug development. Sahu adds, Japans aging population is driving demand for innovative treatments in regenerative medicine, personalised therapies, and AI-driven drug discovery.

Drug Development 66

Drug Development Drug Pricing 66

Pharma Marketing Network

NOVEMBER 15, 2024

But with tight budgets and an evolving landscape, how can pharma professionals effectively connect in 2025 without breaking the bank? Leverage Virtual Platforms The pandemic taught us the power of virtual connectivity, and in 2025, this trend continues. Let’s dive into ten strategies that are both impactful and affordable.

Drug Development 40

Drug Development 40

European Pharmaceutical Review

FEBRUARY 27, 2024

Amgen drug development highlights – November 2023 In November 2023, Phase II trial results for immunotherapy tarlatamab demonstrated an ability to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer trial patients.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

pharmaphorum

NOVEMBER 9, 2022

A recent report from GlobalData noted that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting new drugs to market, and predicted that pharma spending on AI drug discovery would hit $3 billion in 2025. The Pharma.AI

Compounding 111

Compounding Drug Development 111

FDA Law Blog: Biosimilars

MARCH 3, 2025

The American Conference Institutes 3rd Annual Forum on Advanced Therapeutics is scheduled to take place from March 19-20, 2025, at the Seaport Hotel in Boston, MA.

Drug Development 52

Drug Development 52

Express Pharma

MARCH 16, 2025

First, advanced research and development (R&D) and biologics will be critical. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs.

Biosimilars 98

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

JULY 3, 2023

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95

Express Pharma

JUNE 5, 2023

Jakafi’s landmark approval in 2011 galvanised intensive drug development efforts by providing a strong positive investment signal for this market, as Jakafi is a blockbuster agent. Sam Warburton, Oncology Analyst at GlobalData, comments, “Despite MF being a rare disease, it is a blockbuster market with significant commercial potential.

Drug Development 97

Drug Development Biosimilars Compounding 97

pharmaphorum

AUGUST 17, 2022

Together, we aim at making the drug discovery process more efficient and effective in particular when very limited information is available to support drug design.”. It’s part of a larger trend of big pharmas hedging their bets with partnerships with AI firms to find more drug candidates faster.

Compounding 97

Compounding Drug Development 97

pharmaphorum

JANUARY 9, 2023

The development is for expansion of the company’s in-house drug development of biologicals and rare disease targeting and the site is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025.

Drug Development 98

Drug Development 98

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment which is now being evaluated in Phase II clinical trials.

Diabetes 52

Diabetes Drug Development 52

pharmaphorum

JULY 8, 2022

Pharma companies have begun to explore a host of novel digital endpoints that could have far-reaching implications for accelerating drug development and adoption. There is a lot of investment in this area now, but we won’t start to see any significant volume of results until 2024-2025,” remarks Reites. Novel digital endpoints.

Drug Development 100

Drug Development Diabetes 100

pharmaphorum

MARCH 19, 2021

As data and digital technology become vital to every aspect of life sciences, the industry is increasingly looking beyond biologists, chemists, and doctors to drive its drug development – and finding that technology has a chief role to play in the future of medicine. According to an article by Stephens, Zachary D.,

Drug Development 59

Drug Development 59

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. By 2025, pharma’s investment in AI is expected to reach $3 billion. Forging an AI-enabled path toward precision medicine.

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

OCTOBER 9, 2022

UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal.

Drug Development 59

Drug Development 59

Putting Patients First Blog

NOVEMBER 21, 2024

Audience-favorite sessions included a discussion led by Michaeleen Crowel and Martin Riser from the S-3 Group outlining how the recent elections impact the lame duck session and health policy in early 2025. We look forward to building on these conversations at the 2025 Washington Representatives Retreat in Annapolis on November 20 – 21!

Communication 52

Communication Diabetes Drug Development 52

pharmaphorum

AUGUST 9, 2022

An area that offers hope to accelerate an understanding of cancer and speed up drug development is artificial intelligence. Using its AI platform and knowledge of tumour evolution, the startup is able to interpret histogenomic biomarkers to discover and rank genes and proteins with drug target potential.

Drug Development 111

Drug Development 111

pharmaphorum

NOVEMBER 25, 2022

In-house drug development of biologicals and rare disease targeting. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. Technology is to combine within its bounds, he said, so that it is possible to go from start to finish in drug development.

Drug Development 98

Drug Development Pharmaceutical Manufacturing Diabetes 98